These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 34600441)

  • 1. Soluble GC stimulators and activators: Past, present and future.
    Sandner P; Follmann M; Becker-Pelster E; Hahn MG; Meier C; Freitas C; Roessig L; Stasch JP
    Br J Pharmacol; 2024 Nov; 181(21):4130-4151. PubMed ID: 34600441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators.
    Sandner P
    Biol Chem; 2018 Jun; 399(7):679-690. PubMed ID: 29604206
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble Guanylate Cyclase Stimulators and Activators.
    Sandner P; Zimmer DP; Milne GT; Follmann M; Hobbs A; Stasch JP
    Handb Exp Pharmacol; 2021; 264():355-394. PubMed ID: 30689085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Soluble guanylate cyclase stimulators and their potential use: a patent review.
    Sandner P; Vakalopoulos A; Hahn MG; Stasch JP; Follmann M
    Expert Opin Ther Pat; 2021 Mar; 31(3):203-222. PubMed ID: 33395323
    [No Abstract]   [Full Text] [Related]  

  • 5. Novel sGC Stimulators and sGC Activators for the Treatment of Heart Failure.
    Breitenstein S; Roessig L; Sandner P; Lewis KS
    Handb Exp Pharmacol; 2017; 243():225-247. PubMed ID: 27900610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble guanylate cyclase stimulators in pulmonary hypertension.
    Stasch JP; Evgenov OV
    Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases.
    Sandner P; Becker-Pelster EM; Stasch JP
    Nitric Oxide; 2018 Jul; 77():88-95. PubMed ID: 29738821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042).
    Hahn MG; Lampe T; El Sheikh S; Griebenow N; Woltering E; Schlemmer KH; Dietz L; Gerisch M; Wunder F; Becker-Pelster EM; Mondritzki T; Tinel H; Knorr A; Kern A; Lang D; Hueser J; Schomber T; Benardeau A; Eitner F; Truebel H; Mittendorf J; Kumar V; van den Akker F; Schaefer M; Geiss V; Sandner P; Stasch JP
    J Med Chem; 2021 May; 64(9):5323-5344. PubMed ID: 33872507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble Guanylate Cyclase Stimulators and Activators: Novel Therapies for Pulmonary Vascular Disease or a Different Method of Increasing cGMP?
    Koress C; Swan K; Kadowitz P
    Curr Hypertens Rep; 2016 Apr; 18(5):42. PubMed ID: 27118316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The soluble guanylate cyclase stimulator riociguat and the soluble guanylate cyclase activator cinaciguat exert no direct effects on contractility and relaxation of cardiac myocytes from normal rats.
    Reinke Y; Gross S; Eckerle LG; Hertrich I; Busch M; Busch R; Riad A; Rauch BH; Stasch JP; Dörr M; Felix SB
    Eur J Pharmacol; 2015 Nov; 767():1-9. PubMed ID: 26407652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.
    Triposkiadis F; Xanthopoulos A; Skoularigis J; Starling RC
    Heart Fail Rev; 2022 Nov; 27(6):1991-2003. PubMed ID: 35437713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Soluble Guanylate Cyclase Activators and Stimulators in Patients with Heart Failure.
    Liang WL; Liang B
    Curr Cardiol Rep; 2023 Jun; 25(6):607-613. PubMed ID: 37079245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal effects of soluble guanylate cyclase stimulators and activators: a review of the preclinical evidence.
    Stasch JP; Schlossmann J; Hocher B
    Curr Opin Pharmacol; 2015 Apr; 21():95-104. PubMed ID: 25645316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Soluble Guanylyl Cyclase Activators-Promising Therapeutic Option in the Pharmacotherapy of Heart Failure and Pulmonary Hypertension.
    Grześk G; Witczyńska A; Węglarz M; Wołowiec Ł; Nowaczyk J; Grześk E; Nowaczyk A
    Molecules; 2023 Jan; 28(2):. PubMed ID: 36677920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hemodynamic Effects of a Soluble Guanylate Cyclase Stimulator, Riociguat, and an Activator, Cinaciguat, During NO-Modulation in Healthy Pigs.
    Næsheim T; How OJ; Myrmel T
    J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):75-87. PubMed ID: 32662299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation mechanism of human soluble guanylate cyclase by stimulators and activators.
    Liu R; Kang Y; Chen L
    Nat Commun; 2021 Sep; 12(1):5492. PubMed ID: 34535643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nitric oxide-soluble guanylate cyclase-cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase.
    Benza RL; Grünig E; Sandner P; Stasch JP; Simonneau G
    Eur Respir Rev; 2024 Jan; 33(171):. PubMed ID: 38508664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial.
    Armstrong PW; Roessig L; Patel MJ; Anstrom KJ; Butler J; Voors AA; Lam CSP; Ponikowski P; Temple T; Pieske B; Ezekowitz J; Hernandez AF; Koglin J; O'Connor CM
    JACC Heart Fail; 2018 Feb; 6(2):96-104. PubMed ID: 29032136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NO-independent, haem-dependent soluble guanylate cyclase stimulators.
    Stasch JP; Hobbs AJ
    Handb Exp Pharmacol; 2009; (191):277-308. PubMed ID: 19089334
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney.
    Stehle D; Xu MZ; Schomber T; Hahn MG; Schweda F; Feil S; Kraehling JR; Eitner F; Patzak A; Sandner P; Feil R; Bénardeau A
    Br J Pharmacol; 2022 Jun; 179(11):2476-2489. PubMed ID: 34096053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.